Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03372096 · ClinicalTrials.gov registry record · NA
LC Bead LUMI for Prostatic Artery Embolization
A NA study of BPH, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT03372096: Completed NA study of BPH, sponsored by University of North Carolina, Chapel Hill.
NCT03372096 is a NA study of BPH that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 18 participants, below the 67-participant average among 5 other BPH trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03372096, a NA study of BPH, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
Purpose: The purpose of this pilot study is to determine preliminary estimates of the parameters related to the distribution of the study endpoints including: International Prostate Symptom Score (IPSS) and quality of life (QoL) score changes, Qmax (maximum urine flow rate) changes, post void residual volume (PVR) changes, percent prostate infarction and presence of non-target embolization. Participants: 20 adult male subjects with benign hyperplasia will be enrolled in this study. Procedures (methods): This will be a multisite, open label pilot study with a small population undergoing an investigational intervention (prostatic artery embolization) to determine initial safety and potential for efficacy as measured by improvement of lower urinary tract symptoms (LUTS) and decrease in prostate size.
Primary Outcome
The International Prostate Symptom Score (IPSS) is an 8 item Likert questionnaire (7 symptom questions + 1 quality of life question) with scores ranging from 0 to 5, where 0 is less severe. IPSS is a written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of the symptoms of the disease benign prostatic hyperplasia (BPH). Total scores are determined to be Mild (1-7), Moderate (8-19), or Severe (20-35).
Conditions Studied
Interventions
- DEVICE Prostatic Artery Embolization
Study Locations (2)
North Carolina
- UNC Hospitals - Chapel Hill
Virginia
- Vascular Institute of Virginia - Woodbridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-07-13 |
| Est. Completion | 2020-09-03 |
| Phase | NA |
What the finished NCT03372096 record still lists
NCT03372096 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 67-participant average among 5 other BPH trials with a reported enrollment target (73% lower).
The record links to 1 condition, with BPH appearing as the primary indexed condition, and to 1 intervention - of which Prostatic Artery Embolization is the first listed.
NCT03372096 reports a single indexed study location in North Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT03372096 about?
NCT03372096 is a clinical study titled "LC Bead LUMI for Prostatic Artery Embolization". Purpose: The purpose of this pilot study is to determine preliminary estimates of the parameters related to the distribution of the study endpoints including: International Prostate Symptom Score (IPSS) and quality of life (QoL) score changes, Qmax (maximum urine flow rate) changes, post void residu...
What is the current status of trial NCT03372096?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2018-07-13. Estimated completion is 2020-09-03.
What conditions does trial NCT03372096 study?
This clinical trial studies the following conditions: BPH.
What interventions are being tested in trial NCT03372096?
The interventions under investigation include: Prostatic Artery Embolization (DEVICE).
Who is sponsoring clinical trial NCT03372096?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03372096 being conducted?
This trial has 2 study locations across North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BPH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)
COMPLETED · NA
-
MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)
COMPLETED · NA
-
US Imaging for the Assessment of LUTS
RECRUITING
-
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
RECRUITING · Phase 3
-
Effect of Group Preoperative Pelvic Floor Training for HoLEP
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI